Abstract |
The efficacy of intranasally administered neostigmine was tested in 22 patients with generalized myasthenia gravis (MG). Topical therapy to the highly vascularized oropharynx proved to be quickly effective in 5-15 min both clinically and electrophysiologically. Twenty-eight MG patients were then recruited from different centres and their morning doses of oral pyridostigmine were substituted with intranasal neostigmine over a period of 2 or 3 weeks. Intranasal neostigmine proved to be equally efficacious in this regimen. No side-effect was noted even in 4 patients treated in this way for 1 year. Intranasal administration of anti- acetylcholinesterase may be very beneficial: (1) for patients with irregular absorption of oral doses; (2) early in the morning and every time a fast and temporary effect is needed; (3) in bulbar impairment and emergencies, in which a handy atomizer may be life-saving.
|
Authors | A Sghirlanzoni, D Pareyson, C Benvenuti, G Cei, V Cosi, M Lombardi, M Nicora, R Ricciardi, F Cornelio |
Journal | Journal of neurology
(J Neurol)
Vol. 239
Issue 3
Pg. 165-9
(Mar 1992)
ISSN: 0340-5354 [Print] Germany |
PMID | 1573422
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Aerosols
- Neostigmine
- Pyridostigmine Bromide
|
Topics |
- Administration, Intranasal
- Aerosols
- Autoimmune Diseases
(drug therapy, physiopathology)
- Drug Administration Schedule
- Drug Evaluation
- Humans
- Injections, Intravenous
- Muscles
(physiopathology)
- Myasthenia Gravis
(drug therapy, physiopathology)
- Neostigmine
(administration & dosage, therapeutic use)
- Pilot Projects
- Pyridostigmine Bromide
(therapeutic use)
- Severity of Illness Index
|